Abstract: An Interferon Gamma Inducible Protein 16 (IFI16) mutant gene and its use as a marker for predicting, diagnosing, or prognosticating risk or severity of chronic liver disease is described. As a result of performing genomic analysis on NAFLD and NASH patient groups, it was confirmed that the frequency of IFI16 single-nucleotide variants (SNVs) including rs2276404, rs73021847, rs7532207, and rs6940 was increased, and the expression of the IFI16 mutant gene was increased depending on the disease stage of liver disease. The IFI16 SNV was highly expressed in infiltrating macrophages, playing a role in macrophage-induced inflammatory processes, and the IFI16 variant bound more strongly to dsDNA than wild-type IFI16, exacerbating the impaired mitochondrial DNA-sensing response signaling of the IFI16-PYCARD-CASP1 pathway. Thus, the IFI16 mutant gene may be used for predicting, diagnosing, or prognosticating risk or severity of chronic liver disease.

Abstract: The present invention relates to a method for assessing the prognosis or risk stratification of liver cancer by using a clinical specimen mixed with a normal tissue, wherein at least one CpG site that shows a low methylation level in normal and blood tissues but a high methylation level in only a cancer tissue is measured for methylation level.

Abstract: The present invention relates to a method for assessing the prognosis or risk stratification of liver cancer by using a clinical specimen mixed with a normal tissue, wherein at least one CpG site that shows a low methylation level in normal and blood tissues but a high methylation level in only a cancer tissue is measured for methylation level.

Abstract: The present invention relates to: a composition for detecting a gastric cancer marker comprising a preparation for measuring the expression level or methylation level of mRNA of ADCY3 or a protein thereof; a kit for diagnosing gastric cancer, containing the composition; a method for diagnosing gastric cancer by treating a biological sample with the preparation to ascertain whether a material for complementarily binding to the preparation exists and comparing the amount thereof with a control group; a composition for treating and preventing gastric cancer, containing a preparation capable of inhibiting ADCY3 polynucleotide or ADCY3 polypeptide; and a method for treating gastric cancer by administering the composition to an individual. According to the present invention, it is possible to diagnose gastric cancer with high diagnostic sensitivity and specificity using ADCY3 as a marker for diagnosing gastric cancer, and thus can greatly contribute to reducing mortality due to gastric cancer.

Abstract: The present invention relates to statistical machine translation, and provides a machine translation device and a machine translation method that acquire a creation probability for a target language from a single corpus while extracting respective conversion probabilities by extracting syntax conversion knowledge and word translation knowledge from a parallel corpus, model a weighted translation model by allowing each of the conversion knowledge and each of the probabilities to learn using a translation model learning device, and generate a target sentence through decoding processes of a syntax converter and a word translator by applying the translation model to a source sentence input in real time, thereby resolving disadvantages of the existing phrase-based SMT and syntax-based SMT and combining advantages thereof.

Abstract: The present invention relates to a method of predicting reaction to Sorafenib treatment using genetic polymorphism. More specifically, for the reaction to Sorafenib treatment according to the present invention, it is possible to predict the reaction of a test object to Sorafenib treatment by using an anticancer-target gene which is expressed in a biological sample of a liver cancer patient as a biomarker, whereby a proper drug is administered to a liver cancer patient and an optimal treatment effect is attained, so that inconvenience of a patient can be reduced, costs for treatment can be reduced, and an individually tailored chemotherapy can more effectively be implemented by administration of a patient-specific anticancer agent.

Abstract: In an air purifying apparatus for removing contaminants, such as soot and the like, by burning contaminated air while passing the contaminated air through a filter heated by microwaves, the apparatus includes: a housing, which is hollow, and comprises an inlet on one side and an outlet on the other side; a ceramic filter of a longitudinal material, which is arranged in the housing in a longitudinal direction of the housing, and includes a plurality of partition walls formed so that a flow path where contaminated air flows may be divided in plurality; and a microwave generator configured to generate microwaves to be supplied to one end surface of the ceramic filter in a longitudinal direction thereof to heat the one end surface of the ceramic filter in the longitudinal direction.

Abstract: The present invention relates to: a composition for detecting a gastric cancer marker comprising a preparation for measuring the expression level or methylation level of mRNA of ADCY3 or a protein thereof; a kit for diagnosing gastric cancer, containing the composition; a method for diagnosing gastric cancer by treating a biological sample with the preparation to ascertain whether a material for complementarily binding to the preparation exists and comparing the amount thereof with a control group; a composition for treating and preventing gastric cancer, containing a preparation capable of inhibiting ADCY3 polynucleotide or ADCY3 polypeptide; and a method for treating gastric cancer by administering the composition to an individual. According to the present invention, it is possible to diagnose gastric cancer with high diagnostic sensitivity and specificity using ADCY3 as a marker for diagnosing gastric cancer, and thus can greatly contribute to reducing mortality due to gastric cancer.

Abstract: Disclosed is a method for screening a novel cancer therapeutic agent. The cancer therapeutic agent exhibits down-regulation of galectin-3 and fascin-1 or interferes with the interaction between galectin-3 and GSK-3?.

Abstract: In an air purifying apparatus for removing contaminants, such as soot and the like, by burning contaminated air while passing the contaminated air through a filter heated by microwaves, the apparatus includes: a housing, which is hollow, and comprises an inlet on one side and an outlet on the other side; a ceramic filter of a longitudinal material, which is arranged in the housing in a longitudinal direction of the housing, and includes a plurality of partition walls formed so that a flow path where contaminated air flows may be divided in plurality; and a microwave generator configured to generate microwaves to be supplied to one end surface of the ceramic filter in a longitudinal direction thereof to heat the one end surface of the ceramic filter in the longitudinal direction.

Abstract: Disclosed are a cancer marker-detecting composition comprising an agent for measuring an mRNA or protein expression level of eIF3m, a cancer diagnosis kit comprising the same, a method for detecting an eIF3m polynucleotide or protein by treating a biological specimen with the agent to detect a substance binding specifically to the agent and quantitatively comparing the substance between a subject and a normal control, and a method for the treatment and prevention of cancer comprising an agent for down-regulating the expression of an eIF3m polynucleotide or protein.

Abstract: Provided are a method and apparatus for analyzing genotype data plotted in a two-dimensional space. The method includes: connecting points representing the genotype data to a predetermined point to form straight lines and obtaining angles between adjacent straight lines; extracting the two largest angles from the obtained angles; and analyzing the plotted genotype data using three groups of the genotype data separated by the two extracted largest angles. According to the present invention, when the experimental results of classifying genotype are to be analyzed, the two largest angles from the angles obtained by connecting straight lines between points representing each of the genotype data and a predetermined point plotted in a two-dimensional space are detected, and three data regions separated by the detected two largest angles are used to analyze the genotype data. Thus, a large amount of the experimental data for classifying the genotype can be analyzed rapidly and conveniently.

Abstract: Disclosed herein is a composition for molecular imaging comprising a trans-splicing ribozyme coupled with an imaging reporter gene. The trans-splicing ribozyme targets a specific gene associated with a disease. Also disclosed is a molecular imaging method using the composition.

Abstract: The present invention relates to statistical machine translation, and provides a machine translation device and a machine translation method that acquire a creation probability for a target language from a single corpus while extracting respective conversion probabilities by extracting syntax conversion knowledge and word translation knowledge from a parallel corpus, model a weighted translation model by allowing each of the conversion knowledge and each of the probabilities to learn using a translation model learning device, and generate a target sentence through decoding processes of a syntax converter and a word translator by applying the translation model to a source sentence input in real time, thereby resolving disadvantages of the existing phrase-based SMT and syntax-based SMT and combining advantages thereof.

Abstract: Disclosed are a cancer marker-detecting composition comprising an agent for measuring an mRNA or protein expression level of eIF3m, a cancer diagnosis kit comprising the same, a method for detecting an eIF3m polynucleotide or protein by treating a biological specimen with the agent to detect a substance binding specifically to the agent and quantitatively comparing the substance between a subject and a normal control, and a method for the treatment and prevention of cancer comprising an agent for down-regulating the expression of an eIF3m polynucleotide or protein.

Abstract: Disclosed is a method for screening a novel cancer therapeutic agent. The cancer therapeutic agent exhibits down-regulation of galectin-3 and fascin-1 or interferes with the interaction between galectin-3 and GSK-3?.

Abstract: Disclosed herein is a composition for molecular imaging comprising a trans-splicing ribozyme coupled with an imaging reporter gene. The trans-splicing ribozyme targets a specific gene associated with a disease. Also disclosed is a molecular imaging method using the composition.

Abstract: Provided is a polynucleotide including at least 10 contiguous nucleotides of a nucleotide sequence selected from the group consisting of nucleotide sequences of SEQ ID NOS: 1-12 and including a nucleotide at position 101 of the nucleotide sequence, or a complementary polynucleotide thereof.

Abstract: Provided is a polynucleotide for diagnosis or treatment of breast cancer, including at least 10 contiguous nucleotides of a nucleotide sequence selected from the group consisting of nucleotide sequences of SEQ ID No: 1 to SEQ ID No: 5 and comprising a nucleotide at 101st position of the nucleotide sequence, or a complementary polynucleotide thereof.

Abstract: A genetic polymorphism associated with myocardial infarction is provided. More particularly, provided are a polynucleotide including a single nucleotide polymorphism (SNP) or a haplotype associated with myocardial infarction, a polynucleotide hybridized with the polynucleotide, a polypeptide encoded by one of the polynucleotides, an antibody bound to the polypeptide, a microarray and a kit including one of the polynucleotides, a myocardial infarction diagnosis method, a SNP detecting method and a method of screening pharmaceutical compositions for myocardial infarction.